Список проголосовавших за комментарий " Gapping up<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>LTRX</strong> +14.2%, <strong>SMCI</strong> +10.3%, <strong>SYNA</strong> +8.4%, <strong>WYNN</strong> +7.6%, <strong>CVEO</strong> +6.4%, <strong>GHL</strong> +5.1%, (ticking higher), <strong>MXIM</strong> +4.2%</li><li><strong>VMW</strong> +3.9%, (also authorizes an additional $1.2 bln share repurchase), <strong>EMCI</strong> +3.8%, <strong>CMRE</strong> +3.4%, <strong>KLAC</strong> +3.3%, <strong>OSIS</strong> +3.2%</li><li><strong>AAL</strong> +2.8%, <strong>MSFT</strong> +2%, <strong>VVV</strong> +1.8%, <strong>ETFC</strong> +1.6%, <strong>GNTX</strong> +1.6%, <strong>BCR</strong> +1.1%, <strong>INTC</strong> +1.1%, <strong>BT</strong> +0.8%, <strong>GLOP</strong> +0.7%, <strong>LRN</strong> +0.6%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>EPE</strong> +9.9% (light volume, EP Energy enters into a drilling JV w/ Wolfcamp Drillco Operating to fund future oil and natural gas development in its Wolfcamp program)</li><li><strong>GLF</strong> +7.1% (continued strength)</li><li><strong>IMGN</strong> +6.2% (ticking higher; announces that the first patient has been dosed in FORWARD I, the Co's Phase 3 clinical trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer)</li><li><strong>SXL</strong> +1.7% (increases quarterly distribution to $0.52/share from $0.51/share)</li><li><strong>MGM</strong> +1.3% (rebounding following WYNN results)</li><li><strong>MRCY</strong> +1% (prices/increases offering of 6 mln shares at $33/share)</li><li><strong>LVS</strong> +1% (rebounding following WYNN results)</li><li><strong>VLO</strong> +0.7% (increases quarterly dividend to $0.70/share from $0.60/share)</li><li><strong>MPEL</strong> +0.7% (rebounding following WYNN results)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>DQ</strong> +3.1% (initiated with Buy at Craig Hallum)</li><li><strong>WHLR</strong> +2.9% (initiated with a Buy at Wunderlich)</li><li><strong>LUX</strong> +0.7% (upgraded to Buy from Hold at HSBC)</li><li><strong>F</strong> +0.6% (upgraded to Outperform at RBC Capital Mkts)</li><li><strong>FTI</strong> +0.5% (initiated with a Buy at UBS)</li></ul>"